Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Nov 17, 2016 — Data to Be Presented at the 21st Society for Neuro-Oncology Annual Meeting — — Non-clinical Study Supports Initiation of New Clinical Trial of Ad-RTS-hIL-12 in Pediatric Brain Tumors — — Co...
PDF
Nov 15, 2016 BOSTON, Nov. 15, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the publication of data demonstrating enhanced persistence of genetically modified T cells targeting leukemia through utilization of its non-viral Sleeping Beauty...
PDF
Nov 10, 2016 BOSTON, Nov. 10, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Thursday, November 17, 2016 at 4:40 p.m. GMT. As previously announced,...
PDF
Nov 9, 2016 BOSTON, Nov. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced financial results for the third quarter ended September 30, 2016, and provided an update on the Company's recent activities. "ZIOPHARM conti...
PDF
Nov 3, 2016 BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that four abstracts highlighting data from the Company's adoptive cell-based therapeutic programs have been accept...
PDF
Oct 10, 2016 BOSTON, Oct. 10, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced the presentation of preliminary data from the Company's Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. The poster presentatio...
PDF
Oct 5, 2016 BOSTON, Oct. 05, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016 at 2:40 p.m. ET in New York City. About ZI...
PDF
Aug 31, 2016 BOSTON, Aug. 31, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7th, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Bosto...
PDF
Aug 9, 2016 BOSTON, Aug. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company's recent activities. "ZIOPHARM had a very productive first half, with the achievement of pipeline and corporate m...
PDF
Aug 4, 2016 Favorable Long Term Follow-up in Two Trials with Patients Receiving Autologous CAR-T cells and Allogeneic CAR-T cells Potential benefits of Sleeping Beauty approach include reduced costs, complexity, and improved tolerability BOSTON, Aug. 04, 2016 ...
PDF
Page:
1
... NextLast